Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStomach cramps after a Wegovy injection are one of the most commonly reported side effects, and they are almost always a sign your digestive system is adjusting rather than a sign something has gone seriously wrong. Semaglutide slows gastric emptying, which is precisely what helps reduce appetite, but that same mechanism means the gut takes time to settle. Most cramps are mild, short-lived, and fade as your body adapts to the dose. They are not evidence the medicine is harming you, and they are not a reason to stop without first speaking to your prescriber. The NHS medicines page for semaglutide lists gastrointestinal discomfort as an expected and well-documented part of treatment. Wegovy is a prescription-only medicine; a clinician assesses whether it is suitable for you before it is prescribed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A common worry among new Wegovy users is that stomach cramps signal something going wrong — an allergic response, the wrong dose, or the body rejecting the treatment. In almost every case, the opposite framing is closer to the truth. The cramping happens because semaglutide is working as intended. As a GLP-1 receptor agonist, it activates gut-hormone pathways that slow gastric emptying and signal fullness to the brain. The stomach and small intestine are not used to that slower transit, so they contract irregularly, producing the cramping sensation most people describe as sharp-then-dull, or wave-like, typically centred in the lower abdomen.
This adjusting phase is especially noticeable in the first week or two at a new dose. It tends to ease as the gut adapts, though it can return, often more mildly, each time the dose increases. Nausea, loose stools, constipation, and burping frequently accompany the cramps; they are part of the same GI pattern rather than separate problems. None of that makes cramps comfortable, but if you want a fuller picture of what cramps on Wegovy look like and why they happen, that detail is worth reading before your first injection. The Wegovy treatment page covers how semaglutide works in more detail.
If you are finding the pattern difficult to track, some people find it useful to keep a brief note (jotted in a phone app or even on paper in the kitchen next to where they store the pen in the fridge door) of when cramps occur relative to injection day and meal times. That record is genuinely useful if you need to report symptoms to your prescriber.
The vast majority of post-injection cramps are straightforward GI discomfort. There is, however, one pattern that requires urgent medical assessment: severe, persistent pain in the upper or central abdomen that spreads to the back, with or without vomiting, and does not ease within an hour or two. This is the clinical picture of acute pancreatitis, which is a known but infrequent side effect of GLP-1 medicines. In January 2026 the MHRA published a Drug Safety Update specifically drawing attention to this risk across the GLP-1 class, including semaglutide. The update is clear: if you experience pain fitting that description, seek urgent medical help rather than waiting to see if it settles.
Other symptoms worth acting on promptly include signs of serious dehydration from prolonged vomiting or diarrhoea (very dark urine, dizziness, inability to keep fluids down), symptoms of gallbladder problems such as sudden severe upper-right abdominal pain after eating, and any sign of an allergic reaction. You can report suspected side effects to the MHRA via the Yellow Card scheme, which helps the regulator build a fuller picture of real-world tolerability. These serious patterns are genuinely rare. Mentioning them is not to alarm, but because knowing the distinction between routine cramping and a red-flag symptom is exactly what lets people manage confidently rather than anxiously.
If you are uncertain where your symptoms fall, the right step is to contact your prescriber rather than stop the injection unilaterally. You can reach the nume support team seven days a week.
Clinical teams hear a consistent set of strategies from people who get on top of GI side effects. None are complicated. Smaller, lower-fat meals around injection day matter more than most people expect: fatty food prolongs gastric emptying further, so combining a high-fat meal with a new dose compounds the cramping effect. Eating slowly, stopping before full, and staying upright for an hour after eating all reduce the pressure on a stomach that is already emptying sluggishly.
Hydration is worth taking seriously too. Cramps are often worse when someone is mildly dehydrated, partly because the gut motility changes become more pronounced. Plain water is fine; carbonated drinks tend to worsen bloating and can intensify cramping. Alcohol amplifies GI irritation and is best minimised, particularly around injection day.
Injection timing is a variable some people adjust. There is no clinically mandated time of day to take Wegovy, so if cramps reliably peak six to eight hours post-injection, shifting the injection to before bed means you sleep through the worst of it. That is a practical management decision, not a dose change, and does not require clinical approval, though discussing it with your prescriber confirms it suits your specific plan.
People who are wondering whether semaglutide causes cramps more broadly, or who notice the pattern worsening at higher doses, will find more on the mechanisms and management across the Wegovy stomach cramps topic. There is also specific detail available for those whose cramps are worse at night.
Cramps that stay mild and fade within a fortnight at a steady dose rarely need escalation. The threshold for contacting your prescriber is lower than many people assume, though. Cramps severe enough to interrupt sleep regularly, persistent enough to make eating difficult, or unchanged after two to three weeks at the same dose are all worth flagging. So is any new symptom that does not fit the expected GI pattern.
When you do get in touch, concrete information helps: which day after injection cramps start, how long they last, whether anything makes them better or worse, and what meals looked like around the time. Prescribers can consider whether a slower titration schedule, a dose pause, or an anti-nausea medicine alongside treatment would help, all of these are genuine clinical options rather than last resorts. Stopping Wegovy abruptly is rarely the answer and should be a clinical decision, not a unilateral one.
If you are not yet on treatment and are researching what to expect, the free consultation at nume is the place to start, a GPhC-registered prescriber reads your answers the same day, not software, and can address your specific concerns before any prescription is issued. The semaglutide overview and the weight-loss treatment guide offer broader context on what the treatment journey typically involves.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.